HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

China TCM (570.HK) Privatization Update - Investors May Need to Prepare for a Longer Wait

CPMC Holdings (906.HK) - ORG Can't Afford to Lose, But Baosteel Is a Step Ahead

L'Occitane (973.HK) Privatization - The Offer Price Is Good Enough

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Asia Cement (743 HK): $3.22/Share Offer - Really?

Event-Driven

<ul>
<li>So far, about 49.8% of disinterested shares from Irrevocable Undertakings/Non-binding Letters of Support would accept the Share Offer. Success is within reach based on a “good enough” privatization price. </li>
<li>The Share Alternative is mainly aimed at investors who are hoping for the future re-listing of L'Occitane in the overseas markets - They can still get a vantage point.</li>
<li>However, re-listing seems still distant/uncertain. The value of Rollover Shares in the future remains uncertain. Investors would face risks if they choose the Share Alternative. The Cash Alternative is preferred.</li>
</ul>


So far, about 49.8% of disinterested shares from Irrevocable Undertakings/Non-binding Letters of Support would accept the Share Offer. Success is within reach based on a “good enough” privatization price. 
The Share Alternative is mainly aimed at investors who are hoping for the future re-listing of L'Occitane in the overseas markets - They can still get a vantage point.
However, re-listing seems still distant/uncertain. The value of Rollover Shares in the future remains uncertain. Investors would face risks if they choose the Share Alternative. The Cash Alternative is preferred.


L'Occitane (973.HK) - The Privatization Is About to Succeed